Repurposing glucagon
Here, we summarize data supporting the use of GLP -1RAs for the treatment of neurodegenerative diseases , with a focus on AD.
The promise of GLP
Glucagon-like peptide-1 receptor agonists ( GLP -1RAs), established therapies for type 2 diabetes and obesity, are increasingly recognized for their potential in neurodegenerative diseases .
Therefore, this NMA aims to ( 1 ) compare the preventive efficacy of GLP-1 receptor agonists and SGLT2 inhibitors across multiple neurodegenerative diseases ; (2) identify the most effective agents for prevention; and (3) assess their relative safety profiles in preventive use.
Originally developed for diabetes and obesity, GLP-1 receptor agonists ( GLP -1RAs) are drugs that mimic a natural gut hormone to regulate insulin, inflammation and energy use. Recent research suggests that GLP -1RAs may also slow or modify the course of neurodegenerative diseases such as Alzheimer's and Parkinson's.
Understanding Glp 1 Receptor Agonists And Neurodegenerative Diseases Before the Gallery
Frontiers | GLP-1 receptor agonist as a modulator of innate immunity. It gives the article a little more context before the image collection begins.
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation. This note connects the source idea with the visuals in a simple, reader-friendly way.
The Impact of GLP-1 Receptor Agonists on Ocular Disease | Glaucoma. It works as a short bridge between the article summary and the gallery section.
Looking at multiple sources also helps separate the main idea from small decorative details.
These notes are added so the page offers more than images and gives each visitor a clearer reason to keep reading.
